[go: up one dir, main page]

FR2843303B1 - Nouvelles compositions pharmaceutiques destinees au traitement de l'incontinence urinaire - Google Patents

Nouvelles compositions pharmaceutiques destinees au traitement de l'incontinence urinaire

Info

Publication number
FR2843303B1
FR2843303B1 FR0210058A FR0210058A FR2843303B1 FR 2843303 B1 FR2843303 B1 FR 2843303B1 FR 0210058 A FR0210058 A FR 0210058A FR 0210058 A FR0210058 A FR 0210058A FR 2843303 B1 FR2843303 B1 FR 2843303B1
Authority
FR
France
Prior art keywords
treatment
pharmaceutical compositions
urinary incontinence
novel pharmaceutical
musculotropic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
FR0210058A
Other languages
English (en)
Other versions
FR2843303A1 (fr
Inventor
Caroline Rougaignon
Michel Lanquetin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
R&D PHARMA
R & D Pharma
Original Assignee
R&D PHARMA
R & D Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by R&D PHARMA, R & D Pharma filed Critical R&D PHARMA
Priority to FR0210058A priority Critical patent/FR2843303B1/fr
Priority to US10/524,131 priority patent/US20060100182A1/en
Priority to AU2003283153A priority patent/AU2003283153A1/en
Priority to EP03756527A priority patent/EP1526855A2/fr
Priority to PCT/FR2003/002471 priority patent/WO2004014360A2/fr
Publication of FR2843303A1 publication Critical patent/FR2843303A1/fr
Application granted granted Critical
Publication of FR2843303B1 publication Critical patent/FR2843303B1/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention se rapporte au domaine de la chimie thérapeutique et en particulier au domaine de la pharmacotechnie.Elle concerne de nouvelles compositions pharmaceutiques destinées au traitement de l'incontinence urinaire, notamment chez la femme par une association d'une substance cholinergique et musculotrope d'une part, et d'un agent estrogène peu résorbé par voie locale caractérisée en ce que la substance cholinergique et musculotrope est l'oxybutynine ou un de ses sels et que l'agent estrogène peu résorbé est choisi parmi l'estriol, le 16-epiestriol ou l'estradiol sous forme libre, estérifiée et/ou éthérifiée. L'invention se caractérise en outre par le fait que l'administration s'effectue sous une des formes appropriées par la voie vaginale.Utilisation de cette composition pharmaceutique par voie vaginale.
FR0210058A 2002-08-07 2002-08-07 Nouvelles compositions pharmaceutiques destinees au traitement de l'incontinence urinaire Expired - Lifetime FR2843303B1 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
FR0210058A FR2843303B1 (fr) 2002-08-07 2002-08-07 Nouvelles compositions pharmaceutiques destinees au traitement de l'incontinence urinaire
US10/524,131 US20060100182A1 (en) 2002-08-07 2003-08-06 Pharmaceutical compositions for the treatment of urinary incontinence
AU2003283153A AU2003283153A1 (en) 2002-08-07 2003-08-06 Pharmaceutical compositions for the treatment of urinary incontinence
EP03756527A EP1526855A2 (fr) 2002-08-07 2003-08-06 Compositions pharmaceutiques destinees au traitement de l'incontinence urinaire
PCT/FR2003/002471 WO2004014360A2 (fr) 2002-08-07 2003-08-06 Compositions pharmaceutiques destinees au traitement de l'incontinence urinaire

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0210058A FR2843303B1 (fr) 2002-08-07 2002-08-07 Nouvelles compositions pharmaceutiques destinees au traitement de l'incontinence urinaire

Publications (2)

Publication Number Publication Date
FR2843303A1 FR2843303A1 (fr) 2004-02-13
FR2843303B1 true FR2843303B1 (fr) 2006-01-21

Family

ID=30470993

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0210058A Expired - Lifetime FR2843303B1 (fr) 2002-08-07 2002-08-07 Nouvelles compositions pharmaceutiques destinees au traitement de l'incontinence urinaire

Country Status (5)

Country Link
US (1) US20060100182A1 (fr)
EP (1) EP1526855A2 (fr)
AU (1) AU2003283153A1 (fr)
FR (1) FR2843303B1 (fr)
WO (1) WO2004014360A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9173836B2 (en) 2003-01-02 2015-11-03 FemmeParma Holding Company, Inc. Pharmaceutical preparations for treatments of diseases and disorders of the breast
US20110003000A1 (en) * 2009-07-06 2011-01-06 Femmepharma Holding Company, Inc. Transvaginal Delivery of Drugs
GB201601855D0 (en) * 2016-02-02 2016-03-16 Inura Medical Ag Urethral devices for treatment of pathological urological conditions

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6262115B1 (en) * 1995-05-22 2001-07-17 Alza Coporation Method for the management of incontinence
KR20010029519A (ko) * 1996-09-19 2001-04-06 이곤 이 버그 요실금 치료 방법
US6436428B1 (en) * 2000-03-21 2002-08-20 Enhance Pharmaceuticals, Inc. Device and method for treating urinary incontinence in females
CA2461731A1 (fr) * 2001-09-27 2003-04-03 Pharmacia Ab Composition pharmaceutique pour le traitement des troubles urinaires
AU2003287248A1 (en) * 2002-11-12 2004-06-03 Pharmacia And Upjohn Company Combination therapy for postmenopausal female sexual dysfunction comprising an androgen, an estrogen and an antimuscarinic
WO2004052440A1 (fr) * 2002-12-11 2004-06-24 Coloplast A/S Appareil de catheterisme urinaire a composition pharmaceutiquement active
WO2004073679A1 (fr) * 2003-02-13 2004-09-02 Mulholland S Grant Suppositoire uretral renforce
ES2275229T3 (es) * 2003-03-21 2007-06-01 Dynogen Pharmaceuticals, Inc. Metodos para el tratamiento de desordenes del tracto urinario iferior utilizando antimuscarinos y moduladores de la subunidad alfa-2-delta del canal de calcio.

Also Published As

Publication number Publication date
EP1526855A2 (fr) 2005-05-04
FR2843303A1 (fr) 2004-02-13
US20060100182A1 (en) 2006-05-11
WO2004014360A3 (fr) 2004-04-08
AU2003283153A8 (en) 2004-02-25
WO2004014360A2 (fr) 2004-02-19
AU2003283153A1 (en) 2004-02-25

Similar Documents

Publication Publication Date Title
MX2009005307A (es) Nuevas composiciones bajo la forma de ungüento libre de vaselina, que comprenden un derivado de vitamina d y eventualmente un anti-inflamatorio esteroide.
BR0200155A (pt) Tratamento combinado para depressão
TNSN98211A1 (fr) Association d'un inhibiteur d'aldose-reductase et d'un inhibiteur de glycogene-phosphorylase, et composition pharmaceutique la contenant
CA2324904A1 (fr) Composition hormonale topique a effet systemique
TNSN99171A1 (fr) 4-carboxyamino-2-substitue-1,2,3,4-tetrahydroquinoleines, procede pour leur preparation et compositions pharmaceutiques les contenant
BR0317747A (pt) Método de tratamento terapêutico concomitante de um indivìduo, composição farmacêutica, kit, uso de um primeiro agente e um segundo agente, e, métodos de prevenir ou tratar uma doença relacionada com amilóide-b, doença de alzheimer e insuficiência cognitiva suave
TNSN01125A1 (fr) Compositions pharmaceutiques comprenant un inhibiteur de cetp et de l'atorvastatine
TNSN98125A1 (fr) Sels de sertraline, et formes posologiques de sertraline a liberation prolongee, et procedes pour leur preparation
EA200201000A1 (ru) Гормон-заместительная терапия
EP1562897A4 (fr) Inhibiteurs de beta-secretase phenylcarboxamide utilises dans le traitement de la maladie d'alzheimer
BR0108930A (pt) Método de fornecimento de um agente ativo a um tipo celular de interesse, composição farmacêutica, pró-droga ativada por caspase, kit, método de tratamento de mamìferos, uso de um conjugado de caspase e uso de um pró-agente
TNSN98155A1 (fr) Associations de compositions pharmaceutiques d'atorvastatine et d'agents antihypertensifs, et procede pour leur preparation
DE10190041D2 (de) Implantate, Partikel
NZ513810A (en) Compositions and methods for improved delivery of hydrophobic therapeutic agents
ES2162319T3 (es) Uso del agente quelante clioquinol para la fabricacion de una composicion farmaceutica para el tratamiento de la enfermedad de alzheimer.
TR200100812T2 (tr) Akut ağrı tedavisi için fentanil kompozisyon.
BR0009167A (pt) Inibidores de enzima impdh
BR0015346A (pt) Formulação farmacêutica contendo tolterodina e seu uso
WO2006044916A3 (fr) Utilisation d'inhibiteurs de la na+/k+-atpase et leurs antagonistes
EP1658849A3 (fr) combinaisons therapeutiques contenant des agents antihypotensives et antiangiogeniques
TNSN01170A1 (fr) Associations d'agonistes de gaba et d'inhibiteurs d'aldose-reductase.
BR0005765A (pt) Combinação de inibidores de aldose redutase e agentes anti-hipertensivos para o tratamento de complicações diabéticas
ATE429416T1 (de) Cyanophenoxy-carbonsäuren und zusammensetzungen für die freisetzung aktiver substanzen
AR011231A1 (es) Uso de un mejorador de sensibilidad a la insulina y composicion farmaceutica que comprende dicho mejorador
TNSN00231A1 (fr) Forme cristalline de 4-carboxyamino-2-substitue-1,2,3,4- tetrahydroquinoleine, et compositions la contenant

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 15

PLFP Fee payment

Year of fee payment: 16